Access Genetics Enhances Capabilities with New Technology
Access Genetics, operating under OralDNA Labs, has acquired a revolutionary real-time quantitative PCR testing platform. This cutting-edge technology, developed by Sensible Diagnostics, is poised to set a new standard in point-of-care molecular diagnostics.
Transforming Point-of-Care Diagnostics
With the acquisition of Sensible Diagnostics, Access Genetics aims to deliver laboratory-quality test results directly from saliva or swabs in just ten minutes. This provides healthcare professionals with speedy and accurate results, significantly enhancing patient care and decision-making processes.
Innovative Technology for Immediate Results
George Hoedeman, CEO of OralDNA Labs, expressed enthusiasm about the acquisition, stating, "We are proud to add Sensible Diagnostics' state-of-the-art platform to our capabilities, enhancing our ability to provide real-time, actionable results to clinicians and their patients." This commitment to innovation in healthcare diagnostics demonstrates Access Genetics' leadership in the field.
Future Prospects for Dental Diagnostics
The new rapid PCR technology features a sleek, four-channel system and user-friendly microfluidic test cartridges. Initially focusing on the oral microbiome, OralDNA Labs plans to support dental professionals in identifying and treating periodontal disease and its possible connections to broader systemic health issues. It's essential to note that while these platforms are promising, they have not yet received FDA clearance and are not available for commercial sale.
About Access Genetics and OralDNA Labs
Access Genetics is known for its advanced DNA testing services provided at its CLIA-certified and CAP-accredited national reference laboratories. As a pioneer in salivary diagnostics, OralDNA Labs offers a vast array of tests for infectious and genetic markers. With over 24 years of experience, the company prides itself on delivering exceptional customer service and maintaining a strong reputation in the industry.
Contact Information for Media Inquiries
For media inquiries, interested parties can contact Amanda Seaton at 855-672-5362 or reach out through email. This avenue allows easy access for journalists and others seeking information regarding the groundbreaking innovations at Access Genetics.
Frequently Asked Questions
What is the significance of the acquisition by Access Genetics?
The acquisition significantly enhances Access Genetics' capabilities in molecular diagnostics, allowing faster and more accurate test results.
How does the new PCR technology work?
The technology utilizes a real-time quantitative PCR method to provide rapid test results from oral samples.
What areas will the new testing platform focus on?
Initial development will focus on the oral microbiome, specifically aiding in diagnosing periodontal disease.
Are the new tests available for purchase?
No, the platform and related assays currently do not have FDA clearance and are not available for commercial use.
Who can be contacted for more information regarding the acquisition?
Amanda Seaton can be reached for media inquiries at 855-672-5362 for further details regarding the acquisition and future developments.
